Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.54 |
| ▸ | TERT | O14746 | 3/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PPARD | Q03181 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | FABP4 | P15090 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361054 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079548 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL29425333 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079549 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079545 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL17079556 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL30361055 | 1.00 | FAAH (0.57) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL20529761 | 0.98 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL20529769 | 0.98 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 | |
| SCHEMBL20529780 | 0.98 | FAAH (0.55) | FAAHSMN1; SMN2SLC6A5TERTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117858892-A | Compositions and methods for treating and/or preventing proteinopathies | 恢复治疗瑞典公司 | 2024-04-09 | — | — | CN | claimed |
| WO-2024069229-A2 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2024-04-04 | — | — | WO | claimed |
| US-11944688-B2 | Biologically active compounds | SUTURA THERAPEUTICS LTD (GB) | 2024-04-02 | — | — | US | claimed |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | SUTURA THERAPEUTICS LTD (GB) | 2023-05-25 | — | — | US | claimed |
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | SUTURA THERAPEUTICS LTD (TC) | 2023-01-03 | — | — | US | claimed |
| US-20220362332-A1 | ROMO1-DERIVED ANTIMICROBIAL PEPTIDES INCLUDING LYSINE SUBSTITUTION AND VARIANTS THEREOF | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2022-11-17 | — | — | US | claimed |
| EP-3985013-A1 | ROMO1-DERIVED ANTIMICROBIAL PEPTIDES INCLUDING LYSINE SUBSTITUTION AND VARIANTS THEREOF | Korea University Research and Business Foundation (KR) | 2022-04-20 | — | — | EP | claimed |
| CN-114341160-A | ROMO 1-DERIVED ANTIMICROBIAL PEPTIDES AND VARIANTS THEREOF COMPRISING LYSINE SUBSTITUTION | 高丽大学校产学协力团 | 2022-04-12 | — | — | CN | claimed |
| EP-3962933-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | Dana-Farber Cancer Institute, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| WO-2020256392-A1 | ROMO1-DERIVED ANTIMICROBIAL PEPTIDES INCLUDING LYSINE SUBSTITUTION AND VARIANTS THEREOF | 고려대학교산학협력단 | 2020-12-24 | — | — | WO | claimed |
| EP-3737404-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| WO-2020215005-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-22 | — | — | WO | claimed |
| WO-2019118719-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-20 | — | — | WO | claimed |
| EP-3393520-A1 | BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE | Sutura Therapeutics Ltd (TC) | 2018-10-31 | — | — | EP | claimed |
| WO-2017109494-A1 | BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE | SUTURA THERAPEUTICS LTD (TC) | 2017-06-29 | — | — | WO | claimed |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | Bioniz Therapeutics, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| CN-114341160-B | ROMO1 source antimicrobial peptides comprising lysine substitutions and variants thereof | 高丽大学校产学协力团 | 2024-12-17 | — | — | CN | disclosed |
| WO-2018170299-A1 | INHIBITORS OF PROKARYOTIC GENE TRANSCRIPTION AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-09-20 | — | — | WO | disclosed |
| EP-3116538-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS | Fondation The Ark (CH) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015135925-A1 | RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS | FONDATION THE ARK (CH) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11541124-B2 | Biologically active compound conjugated to a stapled or stitched peptide | BPGM, TMPO, SLC7A1 | FAAH 4570/4885SMN1; SMN2 473/4885SLC6A5 449/4885 |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | IL15, IL2, IL15RA | FAAH 2241/4885SMN1; SMN2 606/4885SLC6A5 3634/4885 |
| US-11944688-B2 | Biologically active compounds | BPGM, PICALM, TMPO | FAAH 4637/4885SMN1; SMN2 623/4885SLC6A5 390/4885 |
| US-20230158166-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | BPGM, PICALM, TMPO | FAAH 4637/4885SMN1; SMN2 623/4885SLC6A5 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.